IBDEI0JA ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8961,1,4,0)
 ;;=4^H40.011
 ;;^UTILITY(U,$J,358.3,8961,2)
 ;;=^5005724
 ;;^UTILITY(U,$J,358.3,8962,0)
 ;;=H40.023^^41^469^84
 ;;^UTILITY(U,$J,358.3,8962,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8962,1,3,0)
 ;;=3^Open-Angle w/ Borderline Findings,Hi Risk,Bilateral
 ;;^UTILITY(U,$J,358.3,8962,1,4,0)
 ;;=4^H40.023
 ;;^UTILITY(U,$J,358.3,8962,2)
 ;;=^5005730
 ;;^UTILITY(U,$J,358.3,8963,0)
 ;;=H40.063^^41^469^108
 ;;^UTILITY(U,$J,358.3,8963,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8963,1,3,0)
 ;;=3^Primary Angle-Closure w/o Glaucoma Damage,Bilateral
 ;;^UTILITY(U,$J,358.3,8963,1,4,0)
 ;;=4^H40.063
 ;;^UTILITY(U,$J,358.3,8963,2)
 ;;=^5005746
 ;;^UTILITY(U,$J,358.3,8964,0)
 ;;=H40.243^^41^469^113
 ;;^UTILITY(U,$J,358.3,8964,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8964,1,3,0)
 ;;=3^Residual Stage Angle-Closure Glaucoma,Bilateral
 ;;^UTILITY(U,$J,358.3,8964,1,4,0)
 ;;=4^H40.243
 ;;^UTILITY(U,$J,358.3,8964,2)
 ;;=^5005845
 ;;^UTILITY(U,$J,358.3,8965,0)
 ;;=H40.043^^41^469^121
 ;;^UTILITY(U,$J,358.3,8965,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8965,1,3,0)
 ;;=3^Steroid Responder,Bilateral
 ;;^UTILITY(U,$J,358.3,8965,1,4,0)
 ;;=4^H40.043
 ;;^UTILITY(U,$J,358.3,8965,2)
 ;;=^5005738
 ;;^UTILITY(U,$J,358.3,8966,0)
 ;;=B02.39^^41^470^10
 ;;^UTILITY(U,$J,358.3,8966,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8966,1,3,0)
 ;;=3^Herpes Zoster Eye Disease NEC
 ;;^UTILITY(U,$J,358.3,8966,1,4,0)
 ;;=4^B02.39
 ;;^UTILITY(U,$J,358.3,8966,2)
 ;;=^5000498
 ;;^UTILITY(U,$J,358.3,8967,0)
 ;;=B00.59^^41^470^9
 ;;^UTILITY(U,$J,358.3,8967,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8967,1,3,0)
 ;;=3^Herpes Viral Eye Disease NEC
 ;;^UTILITY(U,$J,358.3,8967,1,4,0)
 ;;=4^B00.59
 ;;^UTILITY(U,$J,358.3,8967,2)
 ;;=^5000476
 ;;^UTILITY(U,$J,358.3,8968,0)
 ;;=B25.9^^41^470^8
 ;;^UTILITY(U,$J,358.3,8968,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8968,1,3,0)
 ;;=3^Cytomegaloviral Disease,Unspec
 ;;^UTILITY(U,$J,358.3,8968,1,4,0)
 ;;=4^B25.9
 ;;^UTILITY(U,$J,358.3,8968,2)
 ;;=^5000560
 ;;^UTILITY(U,$J,358.3,8969,0)
 ;;=H32.^^41^470^6
 ;;^UTILITY(U,$J,358.3,8969,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8969,1,3,0)
 ;;=3^Chorioretinal Disorders in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,8969,1,4,0)
 ;;=4^H32.
 ;;^UTILITY(U,$J,358.3,8969,2)
 ;;=^5005489
 ;;^UTILITY(U,$J,358.3,8970,0)
 ;;=B39.9^^41^470^11
 ;;^UTILITY(U,$J,358.3,8970,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8970,1,3,0)
 ;;=3^Histoplasmosis,Unspec
 ;;^UTILITY(U,$J,358.3,8970,1,4,0)
 ;;=4^B39.9
 ;;^UTILITY(U,$J,358.3,8970,2)
 ;;=^5000638
 ;;^UTILITY(U,$J,358.3,8971,0)
 ;;=B83.0^^41^470^25
 ;;^UTILITY(U,$J,358.3,8971,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8971,1,3,0)
 ;;=3^Visceral Larva Migrans
 ;;^UTILITY(U,$J,358.3,8971,1,4,0)
 ;;=4^B83.0
 ;;^UTILITY(U,$J,358.3,8971,2)
 ;;=^5000799
 ;;^UTILITY(U,$J,358.3,8972,0)
 ;;=B58.01^^41^470^24
 ;;^UTILITY(U,$J,358.3,8972,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8972,1,3,0)
 ;;=3^Toxoplasma Chorioretinitis
 ;;^UTILITY(U,$J,358.3,8972,1,4,0)
 ;;=4^B58.01
 ;;^UTILITY(U,$J,358.3,8972,2)
 ;;=^5000724
 ;;^UTILITY(U,$J,358.3,8973,0)
 ;;=H44.001^^41^470^22
 ;;^UTILITY(U,$J,358.3,8973,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8973,1,3,0)
 ;;=3^Purulent Endophthalmitis,Right Eye,Unspec
 ;;^UTILITY(U,$J,358.3,8973,1,4,0)
 ;;=4^H44.001
 ;;^UTILITY(U,$J,358.3,8973,2)
 ;;=^5005963
 ;;^UTILITY(U,$J,358.3,8974,0)
 ;;=H44.002^^41^470^21
 ;;^UTILITY(U,$J,358.3,8974,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8974,1,3,0)
 ;;=3^Purulent Endophthalmitis,Left Eye,Unspec
 ;;^UTILITY(U,$J,358.3,8974,1,4,0)
 ;;=4^H44.002
